» Articles » PMID: 30938068

Survival After Radiotherapy Versus Radical Cystectomy for Primary Muscle-invasive Bladder Cancer: A Swedish Nationwide Population-based Cohort Study

Abstract

Background: Studies of survival comparing radical cystectomy (RC) and radiotherapy for muscle-invasive bladder cancer have provided inconsistent results and have methodological limitations. The aim of the study was to investigate risk of death after radiotherapy as compared to RC.

Methods: We selected patients with muscle-invasive urothelial carcinoma without distant metastases, treated with radiotherapy or RC from 1997 to 2014 in the Bladder Cancer Data Base Sweden (BladderBaSe) and estimated absolute and relative risk of bladder cancer death and all-cause death. In a group of patients, theoretically eligible for a trial comparing radiotherapy and RC, we calculated risk difference in an instrumental variable analysis. We have not investigated chemoradiotherapy as this treatment was not used in the study time period.

Results: The study included 3 309 patients, of those 17% were treated with radiotherapy and 83% with RC. Patients treated with radiotherapy were older, had more advanced comorbidity, and had a higher risk of death as compared to patients treated with RC (relative risks of 1.5-1.6). In the "trial population," all-cause death risk difference was 6 per 100 patients lower after radiotherapy at 5 years of follow-up, 95% confidence interval -41 to 29.

Conclusion(s): Patient selection between the treatments make it difficult to evaluate results from conventionally adjusted and propensity-score matched survival analysis. When taking into account unmeasured confounding by instrumental variable analysis, no differences in survival was found between the treatments for a selected group of patients. Further clinical studies are needed to characterize this group of patients, which can serve as a basis for future comparison studies for treatment recommendations.

Citing Articles

Latent heterogeneity of muscle-invasive bladder cancer in patient characteristics and survival: A population-based nation-wide study in the Bladder Cancer Data Base Sweden (BladderBaSe).

Haggstrom C, Rowley M, Liedberg F, Coolen A, Holmberg L Cancer Med. 2023; 12(12):13856-13864.

PMID: 37096787 PMC: 10315802. DOI: 10.1002/cam4.5981.


Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities.

Garcia C, Piccinelli M, Tappero S, Panunzio A, Barletta F, Incesu R Int Urol Nephrol. 2023; 55(5):1117-1123.

PMID: 36813873 DOI: 10.1007/s11255-023-03517-0.


Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis.

Qiu J, Zhang H, Xu D, Li L, Xu L, Jiang Y J Oncol. 2022; 2022:7306198.

PMID: 35607328 PMC: 9124076. DOI: 10.1155/2022/7306198.


Trimodal therapy in T2-4aN0M0 bladder cancer--How to select the best candidate?.

Gofrit O, Meirovitz A, Frank S, Rabinovich I, Luwisch H, Yutkin V Cancer Med. 2020; 9(22):8491-8497.

PMID: 32960495 PMC: 7666756. DOI: 10.1002/cam4.3478.


Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: A Swedish nationwide population-based cohort study.

Haggstrom C, Garmo H, de Luna X, Van Hemelrijck M, Soderkvist K, Aljabery F Cancer Med. 2019; 8(5):2196-2204.

PMID: 30938068 PMC: 6536982. DOI: 10.1002/cam4.2126.

References
1.
Liedberg F, Holmberg E, Holmang S, Ljungberg B, Malmstrom P, Mansson W . Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey. Scand J Urol Nephrol. 2011; 46(1):14-8. DOI: 10.3109/00365599.2011.609835. View

2.
Cahn D, Handorf E, Ghiraldi E, Ristau B, Geynisman D, Churilla T . Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer. 2017; 123(22):4337-4345. DOI: 10.1002/cncr.30900. View

3.
Boef A, Dekkers O, le Cessie S, Vandenbroucke J . Reporting instrumental variable analyses. Epidemiology. 2013; 24(6):937-8. DOI: 10.1097/01.ede.0000434433.14388.a1. View

4.
Boef A, van Paassen J, Arbous M, Middelkoop A, Vandenbroucke J, le Cessie S . Physician's preference-based instrumental variable analysis: is it valid and useful in a moderate-sized study?. Epidemiology. 2014; 25(6):923-7. DOI: 10.1097/EDE.0000000000000151. View

5.
Haggstrom C, Liedberg F, Hagberg O, Aljabery F, Strock V, Hosseini A . Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). BMJ Open. 2017; 7(9):e016606. PMC: 5623498. DOI: 10.1136/bmjopen-2017-016606. View